BMO Capital analyst Evan David Seigerman initiates coverage on Mirati Therapeutics (NASDAQ: MRTX) with a Outperform rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE